Background Sputum culture conversion is often used as an early microbiological endpoint in phase 2 clinical trials of tuberculosis treatment on the basis of its assumed predictive value for end-of-treatment outcome, particularly in patients with drug-susceptible tuberculosis. We aimed to assess the validity of sputum culture conversion on solid media at varying timepoints, and the time to conversion, as prognostic markers for end-of-treatment outcome in patients with multidrug-resistant (MDR) tuberculosis.
Introduction
Sputum culture conversion is frequently used as an early microbiological endpoint in phase 2 clinical trials of tuberculosis treatments on the basis of its assumed predictive value for end-of-treatment outcome, particularly in patients with drug-susceptible tuberculosis. In December, 2012, the US Food and Drug Administration (FDA) approved bedaquiline-the fi rst anti-tuberculosis drug developed in more than 40 years-for the treatment of multidrug-resistant (MDR) tuberculosis, on the basis of an accelerated procedure using time to sputum culture conversion and conversion status at 6 months as surrogate microbiological markers of end-of-treatment outcomes. 1 In November, 2013, the European Medicines Agency (EMA) recommended conditional marketing authorisation for another new therapeutic drug, delamanid, for treatment of MDR tuberculosis, on the basis of a dossier using the surrogate microbiological marker of sputum culture conversion status at 2 months. Although ample scientifi c literature exists about 2 month sputum culture conversion as a proxy marker for treatment outcome in patients with drug-susceptible tuberculosis, 2,3 the validity of 2 month and 6 month conversion status as proxy markers for treatment outcome in patients with MDR tuberculosis has not been clearly shown. 4 Nevertheless, the FDA and EMA recognised these markers as suitable indicators of treatment success in these patients, and marketing authorisation followed. 5 We used data from two large cohort studies to assess the validity of time to sputum culture conversion and 2 month and 6 month conversion status as prognostic markers for end-of-treatment outcome in patients with MDR tuberculosis, and to identify optimum timepoints for when sputum culture conversion can be considered as a marker for fi nal treatment outcome.
Methods

Study design and patients
The Preserving Eff ective TB Treatment Study (PETTS) and the DOTS-Plus Pilot Projects Case-Based Study (CBS) designs and patient populations have been previously reported. [6] [7] [8] Briefl y, PETTS was a prospective cohort study of consecutively enrolled adults (aged ≥18 years) with pulmonary MDR tuberculosis who started treatment with second-line drugs between Jan 1, 2005, and Dec 31, 2008, in nine countries (Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea, Taiwan, and Thailand). CBS was a retrospective cohort study that included adult patients (aged ≥18 years) with MDR tuberculosis who started treatment between Jan 1, 2000, and Dec 31, 2003, in four of the fi rst fi ve countries where DOTS-plus projects were approved by the Green Light Committee (Latvia, Peru, the Philippines, and Russia). In both studies, patients were followed up until the end of treatment, or for at least 2 years from the start of treatment, for MDR tuberculosis; monthly sputum microscopy and cultures on solid media were done as part of routine care.
PETTS was approved by the US Centers for Disease Control and Prevention (CDC) institutional review board, and by review boards at all participating sites. Informed consent for participation in the study was obtained from all patients. CBS was approved by the CDC institutional review board. Informed consent was waived by the board because the data were obtained through retrospective review of medical records. For the present secondary analysis, the data were made non-identifi able; thus, this analysis was designated as being exempt from needing ethical review and approval by the CDC.
Defi nitions
We defi ned a positive culture as one or more colonies of Mycobacterium tuberculosis. We defi ned sputum culture conversion as two or more consecutive negative cultures from sputum samples obtained at least 30 days apart. 9 Two negative cultures in sequence counted towards this defi nition even if there were missing cultures between these results. We defi ned time to initial sputum culture conversion as the time in months from the date of start of MDR-tuberculosis treatment to the date of specimen collection for the fi rst of these two consecutive negative cultures. 9 We defi ned sustained sputum culture conversion as an absence of any subsequent positive cultures after conversion. We defi ned sputum culture reversion to positive as at least one subsequent positive culture after initial conversion. We defi ned persistent culture positivity as no culture conversion in patients with a baseline positive culture.
End-of-treatment outcomes were assigned by the clinical sites according to WHO defi nitions at the timenamely, cure (at least fi ve consecutive negative cultures in the fi nal 12 months of treatment [one scant positive is allowed as long as the three last cultures are negative]); treatment completion (successful completion of treatment with fewer than fi ve cultures done in the fi nal 12 months of treatment); death from any cause; failure (two or more [of the fi ve] cultures are positive in the fi nal 12 months, or any one of the fi nal three cultures is positive); and loss to follow-up (interruption for ≥2 months). 9 We defi ned treatment success as cure or completion of treatment. We defi ned poor outcome as failure or death. 9 We defi ned sensitivity as the proportion of patients with sputum culture conversion by month 2 and month 6 among those with successful treatment outcome. We defi ned specifi city as the proportion of patients with no conversion by month 2 and month 6 among those with poor treatment outcome. We defi ned the positive predictive value for each timepoint of conversion as the proportion of patients in whom treatment was successful among all those with initial culture conversion.
Statistical analysis
We analysed time to initial sputum culture conversion with the Kaplan-Meier method and assessed diff erences between groups with the log-rank test. For patients who never converted, time to initial conversion was censored 1 month before their last sputum specimen date (ie, they would no longer be at risk for conversion 1 month before the last observation). To estimate the association of 2 month and 6 month sputum culture conversion with successful treatment outcome, we calculated odds ratios (ORs) and 95% CIs with random-eff ects multivariable logistic regression (SAS version 9.3 Proc Glimmix). Sputum culture conversion was included in the model as the main predictor. Two separate regression models were fi tted for 2 month and 6 month sputum culture conversion. We assessed interactions of culture conversion with each of the covariates of interest. Signifi cant interactions (if detected) were retained, and fi nal multivariable models were adjusted for covariates that had plausible associations with treatment outcome on the basis of the published literature, irrespective of the statistical signifi cance.
We assessed the sensitivity and specifi city of initial culture conversion at 2 months and 6 months in prediction of treatment outcome. Because positive predictive value is dependent on the prevalence of the condition of interest, we assumed 60% prevalence of treatment success on the basis of the average proportion reported in cohorts of patients with MDR tuberculosis worldwide;
10-12 furthermore, we did sensitivity analyses for alternative prevalence rates of 50%, 70%, and 80% (appendix). We plotted receiver operating characteristic curves to visualise the eff ect of use of diff erent timepoints for sputum culture conversion on the balance between sensitivity and specifi city.
To jointly model the sensitivities and specifi cities while accommodating heterogeneity between countries and studies, we used a bivariate random-eff ects generalised linear mixed model (SAS version 9.3 Proc Glimmix). 13, 14 The unit of analysis (the country in the specifi c study) yielded 13 strata. To assess the heterogeneity between studies and countries, and between other factors associated with the prognostic performance of sputum Did not convert 886 (66%) 327 (89%) 1·00
months of treatment
Did not convert 113 (8%) 217 (59%) 1·00
Data are n (%), unless otherwise indicated. OR=odds ratio. *Estimated with univariate random-eff ects logistic regression. See Online for appendix culture conversion, we analysed study-level and individuallevel predictors. We calculated ORs that showed the magnitude and signifi cance of association between each factor and the probability of correct prediction of treatment success (sensitivity) and poor outcomes (specifi city) by conversion status. We summarised the accuracy of results by study and country in forest plots.
We did statistical analyses with SAS (version 9.3).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. EVK, JPC, TD, JE, SES, and MW had full access to all the data from PETTS and EVK, JPC, VMG, and ATW had full access to all the data from CBS. Coauthors from each site had full access to the data from their own site. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The two datasets included 3529 patients, of whom 2043 (58%) had positive sputum cultures at the start of treatment, documented MDR tuberculosis without additional resistance to both fl uoroquinolones and injectable drugs, and one of the treatment outcomes specifi ed by WHO (fi gure 1). The appendix shows characteristics of the study population. Sputum culture conversion was initially recorded in 1738 (85%) of the 2043 patients, but 340 (20%) patients had at least one subsequent positive culture after converting. Ultimately, 1603 (78%) patients had sustained conversion, conversion was not sustained in 135 (7%) patients, and 305 (15%) patients never converted. The median time to initial culture conversion was 3 months (IQR 2-3). HIV co-infected patients had a signifi cantly slower median time to conversion (6 months [IQR 3 to ≥24]) than patients who were HIV-negative (3 months [2] [3] [4] [5] ) or who had an unknown HIV status (2 months [1] [2] [3] ; log-rank p<0·0001). Of patients who reverted to positive, median time after conversion to the fi rst subsequent positive culture was 10 months (IQR 7-14). Overall, 1344 (66%) patients had treatment success, 122 (6%) patients had treatment failure, 246 (12%) patients died, and 331 (16%) patients were lost to follow-up and excluded; all further analyses focused on data for 1712 (84%) of the 2043 patients (fi gure 1). Among patients with treatment success, median time to sputum culture conversion was signifi cantly shorter than in those who had poor outcomes (2 months [IQR 1-3] vs 7 months [3 to ≥24]; log-rank p<0·0001; fi gure 2).
Patients who converted sputum culture at 2 months had a higher chance of treatment success than those with no conversion at 2 months (table 1) . However, in a multivariable analysis adjusted for covariates, 2 month sputum culture conversion had a signifi cant interaction with HIV infection, being signifi cantly associated with treatment success in HIV-negative patients and patients with unknown HIV status, but not in HIV-positive patients (table 2). The odds of treatment success were higher in patients with 6 month sputum culture conversion than in those with no conversion at this time (table 1) . In multivariable analysis adjusted for the same covariates as for 2 month conversion status, the association of conversion with treatment success was substantially greater at 6 months than at 2 months (table 2). There was no signifi cant interaction with HIV status (table 2).
In the comparison of successful versus poor treatment outcomes, sputum culture conversion by the end of 2 months of treatment had a sensitivity of 27·3% and a specifi city of 89·8% (table 3) . The positive predictive value of 2 month sputum culture conversion was 80·2% (95% CI 79·3-81·0). The sensitivity of 2 month sputum culture conversion varied from 14·6% to 49·0% across strata of study-level and individual-level predictors (table 3) . Sensitivity was signifi cantly lower in patients with a history of anti-tuberculosis treatment, cavitary disease, or positive acid-fast-bacilli smears than in those in the complementary groups (table 3) . Specifi city of 2 month conversion was 83·3-94·8% across strata of predictors, except for HIV positivity, the only category with signifi cantly lower specifi city (table 3) . When data were stratifi ed by country, we noted high variability for the empirical sensitivity of 2 month conversion (8·9-69·8%), whereas the range of specifi city (60·0-100%) was narrower (fi gure 3). For sputum culture conversion by the end of 6 months, sensitivity was 91·8% and specifi city was 57·8% (table 3) . The positive predictive value was 76·5% (95% CI 75·6-77·4%). Across strata of predictors, sensitivity of sputum culture conversion at 6 months was 85·7-96·6% (table 3). The sensitivity was signifi cantly lower in patients with a history of anti-tuberculosis treatment, positive acid-fast-bacilli smears, or baseline fl uoroquinolone resistance than in those who did not have the above (table 3) . Specifi city of 6 month sputum culture conversion varied across strata of the covariates (46·3-70·8%) and was signifi cantly higher in patients with positive acid-fast-bacilli smears at baseline (table 3) . When data were stratifi ed by country, we noted high variability in specifi city of 6 month sputum culture conversion (10·0-100%), whereas the range of sensitivity (65·5-100%) was narrower (fi gure 3). Figure 4 shows the eff ect of use of diff erent timepoints of sputum culture conversion on the balance between sensitivity and specifi city. We recorded a high gain in sensitivity from month 2 to month 4 of treatment (from 27·3% to 79·2%) with a relatively smaller decrease in specifi city (from 89·9% to 68·6%). The combined sensitivity and specifi city in prediction of successful treatment outcome reached a maximum between month 6 and month 10 of treatment (fi gure 4).
Discussion
In patients with MDR tuberculosis, time to culture conversion and conversion at 6 months were signifi cantly associated with end-of-treatment outcomes. Sputum culture conversion at 2 months was signifi cantly associated with end-of-treatment outcomes in patients without known HIV infection, but not in those who were HIV positive. The overall association of sputum culture conversion with outcome was substantially greater at 6 months than at 2 months. The 2 month marker of culture conversion had low sensitivity and high specifi city for prediction of treatment success compared with failure or death, whereas the 6 month marker had high sensitivity, but moderate specifi city. The maximum combined sensitivity and specifi city was reached for conversion status assessed between months 6 and 10 of treatment. In view of the average 60% prevalence of treatment success reported in MDR-tuberculosis cohorts worldwide, [10] [11] [12] positive predictive values were relatively high. These results are important because of growing interest in the undertaking of phase 2 trials of potential new treatments for MDR tuberculosis to identify the best regimens for assessment in much larger, longer, and more expensive phase 3 trials (panel).
Surrogate endpoints should satisfy three criteria: correlation with a defi nitive clinical endpoint,
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Data are mean (95% confi dence limit). Data are based on the results of a bivariate generalised linear mixed model adjusted for one covariate at a time. BMI=body-mass index. AFB=acid-fast-bacilli. *Signifi cant diff erence (p<0·05) in predictive values across strata of predictor, on the basis of calculation of odds ratios with respective 95% CIs. †Model for 2 month sputum culture conversion and baseline fl uoroquinolone resistance did not converge. reproducibility, and clinical or biological plausibility. 15 In the context of clinical trials, a low sensitivity of the prognostic marker would bias the results towards the null because a high proportion of patients with eventual successful outcome would be classifi ed as unsuccessful, which might lead to early abandoning of a successful drug or regimen. However, low specifi city of the prognostic marker is of serious concern because it would overestimate the effi cacy of the drug or regimen. Thus, in the context of a clinical trial, moderate specifi city of 58%, as noted for 6 month sputum culture conversion in this study, would mean that 42% of patients who have treatment failure or who die would have culture conversion by 6 months and would have been falsely classifi ed as having a successful outcome, thus overestimating the effi cacy of a new drug or treatmentshortening regimen. Additionally, predictive values of 2 month and 6 month conversion had high variability across strata of some individual patient characteristics; as such, conversion as a predictor of outcome might not be equally useful in all patient groups. For these reasons, both 2 month and 6 month sputum culture conversion seem to be imperfect prognostic markers for treatment outcome in patients with MDR tuberculosis. However, in terms of the balance of prognostic accuracy, 6 month conversion outperformed 2 month conversion. In the present analysis, the positive predictive values of 2 month and 6 month conversion support the use of these proxy markers for end-of-treatment outcomes, but this value is dependent on the prevalence of the condition of interest-treatment success in this analysis. The strength of association, represented by the calculation of the OR, is not dependent on prevalence and allows for assessment of the eff ect of individual patient characteristics. Furthermore, eff ect modifi cation of the association of 2 month conversion with treatment outcome by HIV infection hampers its use as a marker of treatment outcome in HIV-infected patients, although this result should be interpreted with caution because only half the patients received antiretroviral therapy.
The geographical variability in sensitivity and specifi city of both 2 month and 6 month sputum culture conversion might refl ect unmeasured or uncontrolled confounders-eg, countries had a very diff erent prevalence of baseline drug resistance. 6, 16 We cannot exclude variations in laboratory procedures for culture in diff erent countries, although all sites had quality assured laboratories and used solid culture for Such a high degree of geographical variability would thus suggest restricted reproducibility of these markers. 2 month sputum culture conversion has been used as an early microbiological endpoint in clinical trials of drug-susceptible tuberculosis for a long time, on the basis of a correlation with relapse in the series of British Medical Research Council trials. 2 A reanalysis of these data showed that 3 month culture outperforms 2 month culture as a surrogate marker, but both markers are imperfect, with evidence of geographical variation. 18 The results of three large randomised trials of treatmentshortening fl uoroquinolone-containing regimens in patients with drug-susceptible tuberculosis suggest that 2 month culture conversion does not translate directly to inferences about the overall duration of treatment without more careful modelling. [19] [20] [21] [22] For these reasons, and in view of the length of time to culture conversion noted in cohorts of patients with MDR tuberculosis, and the long duration and variability of the continuation phase after culture conversion, 9, 23 extrapolation of 2 month conversion as a surrogate marker of treatment outcome in MDR-tuberculosis drug trials is questionable. In a literature review of 19 studies of patients with MDR tuberculosis prepared by the FDA, most studies reported sputum culture conversion at a median of 2 months. 5 Studies reporting the lowest conversion rates generally had the highest rates of relapse and mortality; however, this association was not universal, and the FDA concluded that "sputum culture conversion can be used to predict the long-term clinical outcome of cure/disease relapse with a reasonable degree of confi dence" in patients with MDR tuberculosis. 5 The high specifi city of 2 month conversion suggests that treatment resulting in conversion by 2 months will probably result in long-term benefi t, but the low sensitivity means that many treatments leading to long-term cure might not meet the criterion of conversion by 2 months.
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Data for predictive value of 6 month sputum culture conversion are also scarce. Our literature search identifi ed only two publications reporting data that would allow for calculation of predictive values and association of 6 month conversion with treatment outcome. 24, 25 In comparisons of successful treatment outcome with failure or death, 6 month conversion had a sensitivity of 89% and specifi city of 88% in a study by Holtz and colleagues, 24 and of 92% and 25%, respectively, in a study by Joseph and colleagues. 25 Sputum culture conversion by the end of month 6 of treatment was signifi cantly associated with treatment success in Holtz and colleagues' study (risk ratio 3·80 [95% CI 2·33-6·22]), but was not signifi cant in Joseph and colleagues' study (1·59 [0·59-4·30] ). The high sensitivity of 6 month conversion suggests that treatments not resulting in conversion by 6 months are unlikely to have lasting benefi t, whereas the low specifi city means that treatments meeting this criterion might not be ultimately eff ective.
Our analysis has important limitations. Results are based on two observational cohort studies (prospective and retrospective), not on randomised clinical trials. Early surrogate markers of the effi cacy of a specifi c treatment remain valid only if the treatment continues according to plan. In our studies, treatment was adjusted as required by the clinical circumstances, meaning that for as long as substantial changes in treatment depended on serial sputum culture results, decreases in sensitivity and specifi city would have been noted. We were unable to take relapses into account because such data were not available. We did not have data for cause of death and could not ascertain that all deaths were tuberculosis related. Furthermore, data for treatment regimens were not available in the CBS study, thus we were unable to include specifi c characteristics of the treatment regimen in this assessment. HIV status, which was an important eff ect modifi er, was unknown for 30% of patients, but this was mainly because of one country that did not routinely test patients with tuberculosis for HIV infection because the prevalence of HIV infection was low in that country at the time of these studies. We excluded a fairly large proportion of patients on the basis of unknown susceptibility to fl uoroquinolone or second-line injectable drugs. That 331 of the 2043 patients included in the study were lost to follow-up during or after treatment is notable. These patients were excluded from analysis, but they might have represented poor treatment outcomes compared with those who were fully retained in the treatment cohorts. The number of patients in some predictors' strata was low, which reduces the power of the multivariable analysis. Moreover, cultures were done on solid media, and the results might diff er if liquid media is used. Our analysis focused on the use of sputum culture conversion as a potential surrogate endpoint for controlled clinical trials of MDR tuberculosis. These fi ndings do not necessarily apply to clinical practice. Sputum culture conversion is only one part of assessment of the eff ect of treatment, and patients are reassessed every time they see their physician, which can be daily for inpatients or monthly for ambulatory patients. A patient having sputum culture conversion at 2 months would give some assurance that treatment is eff ective. However, the absence of conversion at 2 months might be too early to change treatment, unless the patient's condition is deteriorating, because the median time to conversion in our study was 3 months. Conversely, 6 months might be too long to wait for culture conversion, again, dependent on the overall clinical picture. In most patients in most situations, physicians would not wait for sputum culture conversion at 6 months before reassessing the patient and adjusting treatment.
Confi rmatory phase 3 trials are expensive and timeconsuming, especially for MDR tuberculosis, 4 so the question of which are the shortest, simplest, most eff ective, and safest regimens to be tested in these trials becomes a major public health challenge. As new drugs and new combinations of drugs are being investigated for treatment of patients with MDR tuberculosis, 26 and while novel adaptive trial designs are being proposed to rapidly identify the best drugs or drug combinations to be advanced to phase 3 trials, 27 the defi nition and relevance of the best surrogate marker to be used to measure treatment effi cacy is of paramount importance. Our present fi ndings show that time to sputum culture conversion on solid media, conversion at 6 months, and at 2 months, in patients without known HIV infection could be considered as surrogate markers of treatment outcome in trials of MDR tuberculosis. However, the overall association with outcome was substantially stronger for 6 month than for 2 month conversion, and 6 month conversion was valid both in HIV-infected patients, and in those without known HIV infection. Despite these fi ndings, our results show a series of major limitations that should be taken into consideration when these markers are used as surrogates of treatment effi cacy in patients with MDR tuberculosis. 
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